Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management....
| Metric Name | Value | Trend | |
|---|---|---|---|
| Dividend Yield | 0.0% | ||
| P/E Ratio | 12.3x | ||
| Revenue | 631.4 M | ||
| Net Income to Company | 69.19 M |
| COLL | Peers | Sector | |
|---|---|---|---|
Market Cap | 868.2 M | 1.602 B | 62.851 M |
Price % of 52 Week High | 63.9% | 44.3% | 59.8% |
Dividend Yield | 0.0% | 0.0% | 0.0% |
Shareholder Yield | -27.3% | 1.6% | -0.7% |
1 Year Price Total Return | -23.8% | -30.5% | -12.5% |
Beta (5 Year) | 0.76 | 0.72 | 0.64 |
| (presentment in millions) | Trailing Twelve Months | Fiscal Quarters | |||
|---|---|---|---|---|---|
| Period Ending | Dec-22 | Dec-23 | Dec-24 | Dec-23 | Dec-24 |
| Income Statement | |||||
| Revenue | 464 | 567 | 631 | 150 | 182 |
| Operating Income | 38 | 191 | 200 | 62 | 44 |
| Net Profit | (25) | 48 | 69 | 32 | 13 |
| Diluted EPS | -0.74 | 1.29 | 1.86 | 0.92 | 0.35 |
| EBITDA | 172 | 340 | 369 | 97 | 100 |
| Balance Sheet | |||||
| Cash & ST Invest. | 174 | 311 | 163 | 311 | 163 |
| Current Assets | 420 | 538 | 482 | 538 | 482 |
| Total Assets | 1,174 | 1,143 | 1,664 | 1,143 | 1,664 |
| Current Liabilities | 434 | 458 | 510 | 458 | 510 |
| Total Liabilities | 979 | 948 | 1,435 | 948 | 1,435 |
| Total Equity | 195 | 195 | 229 | 195 | 229 |
| Total Debt | 709 | 674 | 980 | 674 | 980 |
| Cash Flow Statement | |||||
| Cash Flow Operations | 124 | 275 | 205 | 73 | 85 |
| Cash From Investing | (574) | (71) | (288) | (25) | (12) |
| Cash From Financing | 437 | (140) | (61) | (68) | (41) |
| Free Cash Flow | 123 | 274 | 203 | 73 | 84 |